A. Pastor

发表

Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation

J. Escrivá, S. Aliño, J. Ruiz, 2015, International journal of molecular sciences.

Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis.

A. Pastor, R. Menéndez, M. Cremades, 1997, The European respiratory journal.

Effect of cyclosporin on lung diffusing capacity in renal transplant patients

A. Pastor, M. Cremades, L. Pallardó, 1995, Transplant international : official journal of the European Society for Organ Transplantation.

Pharmacogenetics of Immunosuppressants in Solid Organ Transplantation: Time to Implement in the Clinic

S. Aliño, M. J. Herrero, V. Bosó, 2016 .

Lymphoproliferative disease after lung and heart-lung transplantation: first description in Spain.

A. Pastor, A. Solé, P. Morales, 2005, Transplantation proceedings.

Diagnostic value of cytokeratin fragment 19 (CYFRA 21-1) in bronchoalveolar lavage fluid in lung cancer.

A. Pastor, R. Menéndez, M. Cremades, 1998, Respiratory medicine.

Steroid withdrawal in lung transplant recipients.

A. Pastor, A. Solé, M. de la Torre, 2005, Transplantation proceedings.

Pulmonary tuberculosis in lung and heart-lung transplantation: fifteen years of experience in a single center in Spain.

A. Pastor, A. Solé, P. Morales, 2005, Transplantation proceedings.

Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.

A. Pastor, A. Solé, M. de la Torre, 2008, Transplantation proceedings.

Mechanisms of Action of Quinolones against Staphylococci and Relationship with Their in vitro Bactericidal Activity

A. Pastor, J. Pemán, José P. Martínez, 1999, Chemotherapy.

In-vitro postantibiotic effect of sparfloxacin and ciprofloxacin against Pseudomonas aeruginosa and Enterococcus faecalis.

A. Pastor, J. Pemán, E. Cantón, 1994, The Journal of antimicrobial chemotherapy.

Invasive scedosporiosis in lung transplant recipients: A nine-year retrospective study in a tertiary care hospital.

A. Pastor, A. Solé, J. Pemán, 2021, Revista iberoamericana de micologia.

Risk factors, survival, and impact of prophylaxis length in cytomegalovirus‐seropositive lung transplant recipients: A prospective, observational, multicenter study

A. Pastor, A. Solé, J. Cifrián, 2017, Transplant infectious disease : an official journal of the Transplantation Society.

Efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease in lung transplant recipients (CYTOCOR STUDY): an open-label, randomised, non-inferiority clinical trial

A. Pastor, J. Torre-Cisneros, P. Ussetti, 2019, BMJ Open.

Genotype and Allele Frequencies of Drug-Metabolizing Enzymes and Drug Transporter Genes Affecting Immunosuppressants in the Spanish White Population

S. Aliño, M. J. Herrero, V. Bosó, 2014, Therapeutic drug monitoring.

A Multicenter Study of Valganciclovir Prophylaxis up to Day 120 in CMV‐Seropositive Lung Transplant Recipients

A. Pastor, A. Solé, J. Cifrián, 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation

M. Sanz, A. Pastor, A. Solé, 2018, Leukemia & lymphoma.

Antibody response to human cytomegalovirus (HCMV) glycoprotein B (gB) in AIDS patients with HCMV end‐organ disease

L. Cardeñoso, A. Pastor, M. Blanes, 1998, Journal of medical virology.

Patient-reported symptoms and functioning as indicators of mortality in advanced cystic fibrosis: A new tool for referral and selection for lung transplantation.

J. Escrivá, A. Quittner, D. Hervás, 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Author ’ s Accepted Manuscript Patient reported symptoms and functioning as indicators of mortality in advanced cystic fibrosis ; a new tool for referral and selection for lung transplantationA new tool for cystic fibrosis management

A. Quittner, A. Pastor, G. Sales, 2016 .

Conversion from cyclosporine to tacrolimus stabilizes the course of lung function in lung transplant recipients with bronchiolitis obliterans syndrome.

A. Pastor, A. Solé, J. Cifrián, 2007, Transplantation proceedings.

Tuberculosis Following Lung Transplantation. A 27-Year Spanish Multicenter Experience. Incidence, Presentation, Prevention and Treatment with Rifampicin

B. Saez, A. Pastor, A. Solé, 2020, Archivos de Bronconeumología (English Edition).

Tuberculosis Following Lung Transplantation. A 27-Year Spanish Multicenter Experience. Incidence, Presentation, Prevention and Treatment with Rifampicin.

B. Saez, A. Pastor, A. Solé, 2019, Archivos de bronconeumologia.

Killing of Gram-Negative Bacteria by Ciprofloxacin within both Healthy Human Neutrophils and Neutrophils with Inactivated O2-Dependent Bactericidal Mechanisms

A. Pastor, J. Pemán, E. Cantón, 1999, Chemotherapy.

A Multicenter Study of Valganciclovir Prophylaxis up to Day 120 in CMV‐Seropositive Lung Transplant Recipients

A. Pastor, J. Cifrián, J. Gavaldà, 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.